Warning letter
Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals: warning letter of Dec 17, 2024
FDA warning letter 694687 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 694687 |
|---|---|
| Company | Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Dec 17, 2024 |
| Posted date | Mar 11, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 210.1(b), 200.10(b), 201.115, 211.46(b), 211.67(b), 211.94(c), 211.113(b), 211.192 |
| Inspection city | Irving |
| Inspection ZIP | 75063 |
| Inspection start date | May 28, 2024 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: